NIH Guide: Weekly Index for February 19, 2021

Funding Opportunities

• Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
  (PAR-21-120)
  John E. Fogarty International Center
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): August 3 2021, August 3, 2022, August 3,2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34 - Clinical Trial Not Allowed)
  (PAR-21-146)
  National Institute of General Medical Sciences
  Application Receipt Date(s): May 26, 2021; May 26, 2022; May 26, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• The FDA's Cooperative Agreement Program for States and Territories to Implement a National Produce Safety Program (U2F) Clinical Trials Not Allowed
  (PAR-21-174)
  Food and Drug Administration
  Application Receipt Date(s): April 23, 2021 by 11:59 PM Eastern Time. March 1, 2022, 2023 by 11:59 PM Eastern Time.
• Drug Development Tools Research Grants (U01) Clinical Trial Optional
  (PAR-21-178)
  Food and Drug Administration
  Application Receipt Date(s): May 25, 2021 by 11:59 PM Eastern Time May 3, 2022 by 11:59 PM Eastern Time May 3, 2023 by 11:59 PM Eastern Time
• Minor Use Minor Species Development of Drugs (R01)
  (PAR-21-179)
  Food and Drug Administration
  Application Receipt Date(s): July 30, 2021; February 4, 2022; July 29, 2022; February 3, 2023; July 28, 2023; February 2, 2024 By 11:59 PM Eastern Time.
• Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)
  (RFA-AI-21-007)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 30, 2021
• Limited Competition: Facility and Building System Upgrades Support for the Regional Biocontainment Laboratories (G20 Clinical Trial Not Allowed)
  (RFA-AI-21-022)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): April 16, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)
  (RFA-CA-21-030)
  National Cancer Institute
  Application Receipt Date(s): June 02, 2021
• Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
  (RFA-DK-21-005)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 22, 2021
• Renewal : UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (U01) Clinical Trials Optional
  (RFA-FD-21-017)
  Food and Drug Administration
  Application Receipt Date(s): May 25, 2021 by 11:59 PM Eastern Time.
• Dermal Physiologically-based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-solvent following the Application of Generic Dermatological Products (U01) Clinical Trial Optional
  (RFA-FD-21-019)
  Food and Drug Administration
  Application Receipt Date(s): April 22, 2021 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Impulse Oscillometry Endpoint Sensitivity to Regional Lung Function Changes using Computational Fluid Dynamics (CFD) (U01) Clinical Trial Required
  (RFA-FD-21-020)
  Food and Drug Administration
  Application Receipt Date(s): April 26, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Training Alliance to Enhance Produce Safety and FDA Food Safety Modernization Act Compliance (U2F) Clinical Trial Not Allowed
  (RFA-FD-21-024)
  Food and Drug Administration
  Application Receipt Date(s): April 19, 2021, by 11:59 PM Eastern Time
• Alliance to Support Integrated Food Safety System (IFSS) Activities (U2F) Clinical Trials Not Allowed
  (RFA-FD-21-029)
  Food and Drug Administration
  Application Receipt Date(s): April 23, 2021 by 11:59 PM Eastern Time.
• Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) Clinical Trials Not Required
  (RFA-FD-22-001)
  Food and Drug Administration
  Application Receipt Date(s): February 15, 2022; February 13, 2024: by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Tobacco Regulatory Science (R01 Clinical Trial Optional)
  (RFA-OD-21-002)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): July 14, 2021, February 15, 2022, July 14, 2022, February 14, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Fogarty Global Trauma and Injury Research Training Program (D43 Clinical Trial Optional)
  (RFA-TW-21-003)
  John E. Fogarty International Center
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): April 16, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.